A hexapeptide ghrelin-receptor agonist that stimulates pituitary GH release. Less selective than ipamorelin — it produces measurable increases in cortisol and prolactin alongside GH.
Approved in Japan as a diagnostic agent for assessing growth hormone secretory reserve, which is its one well-established human use. Evidence for therapeutic use is absent.
Not FDA-approved. Approved in Japan as a diagnostic (Pralmorelin/GHRP Kaken). Prohibited in sport (WADA S2).
Cortisol and prolactin elevation distinguish it from selective agents. Long-term human safety not characterised.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.